AUTHOR=Heinke Reinhard , Chevallay Eric , Chrysalidis Katerina , Cocolios Thomas E. , Duchemin Charlotte , Fedosseev Valentin N. , Hurier Sophie , Lambert Laura , Leenders Benji , Marsh Bruce A. , van der Meulen Nicholas P. , Sprung Peter , Stora Thierry , Tosato Marianna , Wilkins Shane G. , Zhang Hui , Talip Zeynep TITLE=Efficient Production of High Specific Activity Thulium-167 at Paul Scherrer Institute and CERN-MEDICIS JOURNAL=Frontiers in Medicine VOLUME=8 YEAR=2021 URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.712374 DOI=10.3389/fmed.2021.712374 ISSN=2296-858X ABSTRACT=
Thulium-167 is a promising radionuclide for nuclear medicine applications with potential use for both diagnosis and therapy (“theragnostics”) in disseminated tumor cells and small metastases, due to suitable gamma-line as well as conversion/Auger electron energies. However, adequate delivery methods are yet to be developed and accompanying radiobiological effects to be investigated, demanding the availability of 167Tm in appropriate activities and quality. We report herein on the production of radionuclidically pure 167Tm from proton-irradiated natural erbium oxide targets at a cyclotron and subsequent ion beam mass separation at the CERN-MEDICIS facility, with a particular focus on the process efficiency. Development of the mass separation process with studies on stable 169Tm yielded 65 and 60% for pure and erbium-excess samples. An enhancement factor of thulium ion beam over that of erbium of up to several 104 was shown by utilizing laser resonance ionization and exploiting differences in their vapor pressures. Three 167Tm samples produced at the IP2 irradiation station, receiving 22.8 MeV protons from Injector II at Paul Scherrer Institute (PSI), were mass separated with collected radionuclide efficiencies between 11 and 20%. Ion beam sputtering from the collection foils was identified as a limiting factor.